Compare Invesco DB Agriculture Fund (DBA) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Medpace Holdings Inc — how do they compare? Invesco DB Agriculture Fund trades at $28.33 (market cap $1.32B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 12.7× Invesco DB Agriculture Fund's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Invesco DB Agriculture Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Medpace Holdings Inc for 14 Days on average.
| DBA | MEDP | |
|---|---|---|
Market Cap | $1.32B | $16.82B |
Volume | 771,657 | 223,093 |
52-Week High | $29.49 | $630.19 |
52-Week Low | $25.44 | $393.42 |
Typical Hold Time | 24 Days | 14 Days |
Sector | — | Health |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.295, down 0.68% today, with a bearish technical signal from moving averages but neutral oscillators. The ETF has delivered strong 12.4% YTD returns, outperforming the S&P 500 in recent months according to Zacks Investment Research (2026-07-30). Recent news highlights agricultural ETF strength driven by weather risks and geopolitical tensions, though the fund carries a relatively high 0.85% expense ratio.
The agricultural commodities exposure positions DBA for potential upside from supply chain disruptions and global demand, but investors face volatility risks from commodity price swings and geopolitical uncertainty. Analyst sentiment remains mixed with Seeking Alpha maintaining a Hold rating (2026-09-22) while noting bullish long-term trends since 2020.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
